An Open-Label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNy) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

This Study is
No Longer Enrolling

Details
Age

Child

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Study ID

Protocol Number: 19-0105

More information available at ClinicalTrials.gov: NCT03312751

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers